| |  John C. Martin, PhD
Chairman and Chief Executive OfficerJohn C. Martin, PhD
Chairman and Chief Executive Officer
Dr. Martin joined Gilead Sciences in 1990 and currently serves as Chairman of the Board of Directors and Chief Executive Officer. He served as President and Chief Executive Officer from 1996 through May 2008. Prior to joining Gilead, Dr. Martin held several leadership positions at Bristol-Myers Squibb and Syntex Corporation.
Dr. Martin is a member of the Board of Directors of the California Healthcare Institute and Gen-Probe Incorporated. He also serves on the University of Southern C... |
| | John F. Milligan, PhD
President and Chief Operating OfficerJohn F. Milligan, PhD
President and Chief Operating Officer
Dr. Milligan joined Gilead Sciences in 1990 as a research scientist and was made Director of Project Management and Project Team Leader for the Gilead Hoffmann-La Roche Tamiflu® collaboration in 1996. In 2002, Dr. Milligan was appointed Chief Financial Officer. He was named Chief Operating Officer in 2007 and President in 2008.
Dr. Milligan was named "Bay Area CFO of the Year" in 2006 for companies with revenues greater than $500 million, and he was named the top biotechnology indu... |
| | Norbert W. Bischofberger, PhD
Executive Vice President, Research and Development and Chief Scientific OfficerNorbert W. Bischofberger, PhD
Executive Vice President, Research and Development and Chief Scientific Officer
Dr. Bischofberger joined Gilead Sciences in 1990 and has served Executive Vice President for Research and Development since 2000 and Chief Scientific Officer since 2007. Prior to joining Gilead, Dr. Bischofberger was a Senior Scientist in Genentech’s DNA Synthesis Group from 1986 until 1990.
Dr. Bischofberger received a PhD in organic chemistry from Zurich’s Eidgenossische Technische Hochshule and performed postdoctoral research in steroid chemistry at Syntex. He also performed ad... |
| | Gregg H. Alton
Executive Vice President, Corporate and Medical AffairsGregg H. Alton
Executive Vice President, Corporate and Medical Affairs
Gregg Alton joined Gilead Sciences in 1999. From 2000 to 2009 he served as General Counsel. In his current role, Mr. Alton is responsible for legal affairs, corporate compliance and quality, government affairs, medical affairs, public affairs and international access activities. Prior to joining Gilead, Mr. Alton was an attorney at the law firm of Cooley Godward, LLP, where he specialized in mergers and acquisitions, corporate partnerships and corporate finance transactions for hea... |
| | Kevin Young CBE
Executive Vice President, Commercial OperationsKevin Young CBE
Executive Vice President, Commercial Operations
Kevin Young joined Gilead Sciences in 2004 as Executive Vice President of Commercial Operations. Mr. Young is a 28-year veteran of the biopharmaceutical industry, with a career that spans a variety of therapeutic categories including cardiology, oncology, rheumatology, hepatitis and HIV/AIDS. He previously held positions at Amgen, Inc. and AstraZeneca Pharmaceuticals (formerly ICI Pharmaceuticals). During his 12 years at Amgen, Mr. Young held a number of positions in Europe and the United Sta... |
| | Kristen M. Metza
Senior Vice President, Human ResourcesKristen M. Metza
Senior Vice President, Human Resources
Ms. Metza joined Gilead Sciences as Vice President, Human Resources in 2006 and was promoted to her current role in July 2007. As Senior Vice President, Human Resources, she is responsible for designing and implementing HR strategies and programs that attract, develop and retain talent for a high-performing workforce. To support Gilead’s growth and continued success, Ms. Metza is focused on employee engagement and motivation. Specifically, she is establishing a new framework for management and l... |
| | Robin L. Washington
Senior Vice President and Chief Financial OfficerRobin L. Washington
Senior Vice President and Chief Financial Officer
Ms. Washington joined Gilead as Senior Vice President and Chief Financial Officer in May 2008. In this role, she oversees Gilead's worldwide Finance and Investor Relations functions. Prior to joining Gilead, Ms. Washington served as Chief Financial Officer of Hyperion Solutions, an enterprise software company that was acquired by Oracle Corporation in March 2007. Ms. Washington also spent nearly 10 years at PeopleSoft, a provider of enterprise application software, most recently in the role o... |
| |
|
